We’re pleased to share the publication of a new study in Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring, based on data from the Global Alzheimer’s Platform Bio-Hermes study. This research explores how well new blood-based tests can detect signs of Alzheimer’s disease in people experiencing early symptoms, such as mild cognitive impairment (often a precursor to dementia) or mild dementia.
The study found that two leading blood biomarkers — plasma Aβ42/40 and p-Tau217 — closely match results from amyloid PET scans. Amyloid PET is a specialised brain imaging technique that can reveal amyloid plaques, one of the key biological hallmarks of Alzheimer’s disease. The study reinforces amyloid PET as the reference standard for defining pathology and validating emerging biomarkers, while highlighting how blood tests can complement imaging in scalable screening and patient selection pathways.
Overall, the findings suggest that the future of Alzheimer’s diagnosis will rely on a multimodal approach — combining advanced imaging, fluid biomarkers like blood tests, and clinical information. Together, these tools can enable more confident diagnoses, improve trial enrolment, and guide therapeutic decisions.
We’re proud to contribute imaging expertise and scientific rigour to research that is helping shape this rapidly evolving diagnostic landscape.
Read the full research article here
